title: The decrease of particle-induced osteolysis after a single dose of bisphosphonate.
abstract: The most common cause of implant failure in joint replacement is aseptic loosening due to particle-induced osteolysis. Bisphosphonates have been shown to be effective against particle-induced osteolysis when administered daily. We investigated the effect of a single subcutaneous dose of a more potent third generation bisphosphonate on particle-induced osteolysis. We utilized the murine calvaria osteolysis model in C57BL/J6 mice. Bone resorption was measured as resorption within the midline suture using Giemsa staining. Twenty-eight mice were used, seven per group. Seven animals were treated with a single dose of zoledronic acid (ZA) directly after surgery and seven animals were treated four days postoperatively. For statistical analysis one-way ANOVA and a Student's t-test were used. Bone resorption was 0.26+/-0.09 mm(2) in animals with particle implantation, 0.14+/-0.05 mm(2) in animals with particle implantation and ZA treatment directly after surgery (p = 0.0047), and 0.15+/-0.05 mm(2) in animals with particle implantation and ZA treatment on the fourth postoperative day (p = 0.006). In conclusion, particle-induced bone resorption was markedly decreased by a single s.c. dose of a third generation bisphosphonate. This important new finding holds great promise, because single dose treatment of particle-induced osteolysis may reduce side effects compared to repeated application of bisphosphonates.
authors.affiliation: Department of Orthopaedics, University of Duisburg-Essen, Pattbergstrasse 1-3, 45239 Essen, Germany. mariusvonknoch@yahoo.com
authors.forename: Marius
authors.initials: M
authors.lastname: von Knoch
authors.forename: Christian
authors.initials: C
authors.lastname: Wedemeyer
authors.forename: Andreas
authors.initials: A
authors.lastname: Pingsmann
authors.forename: Fabian
authors.initials: F
authors.lastname: von Knoch
authors.forename: Gero
authors.initials: G
authors.lastname: Hilken
authors.forename: Christoph
authors.initials: C
authors.lastname: Sprecher
authors.forename: Frank
authors.initials: F
authors.lastname: Henschke
authors.forename: Bertram
authors.initials: B
authors.lastname: Barden
authors.forename: Franz
authors.initials: F
authors.lastname: Löer
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D005549:Foreign-Body Reaction / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D007093:Imidazoles / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D008297:Male; D008422:Materials Testing; D051379:Mice; D008810:Mice, Inbred C57BL; D010014:Osteolysis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control; D010316:Particle Size; D020959:Polyethylene / Q000009:adverse effects*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D001672:Biocompatible Materials; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D020959:Polyethylene